Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23489977 | 0.83 | GABRA1 (0.38) | GABRA1GABRB1LMNACRHR1HTT | |
| SCHEMBL23363345 | 0.83 | GABRA1 (0.38) | GABRA1GABRB1LMNACRHR1HTT | |
| SCHEMBL10153871 | 0.81 | DRD1 (0.34) | GABRA1GABRB1LMNACRHR1HTT | |
| SCHEMBL12356952 | 0.80 | GABRA1 (0.46) | GABRA1GABRB1LMNATSHRMAPK1 | |
| SCHEMBL17574705 | 0.78 | GABRA1 (0.45) | GABRA1GABRB1LMNATSHRMAPK1 | |
| SCHEMBL2738314 | 0.77 | CCR1 (0.38) | LMNAKMT2A | |
| SCHEMBL23434930 | 0.77 | GABRA1 (0.43) | GABRA1GABRB1 | |
| SCHEMBL15764109 | 0.77 | GABRA1 (0.54) | GABRA1GABRB1LMNATSHRMAPK1 | |
| SCHEMBL8214469 | 0.77 | GABRA1 (0.43) | GABRA1GABRB1LMNATSHRMAPK1 | |
| SCHEMBL12848879 | 0.76 | GABRA1 (0.39) | GABRA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2018118947-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885GABRB1 2621/4885LMNA 3372/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | GABRA1 2191/4885GABRB1 2743/4885LMNA 3301/4885 |
| US-11548871-B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB1 1305/4885LMNA 1879/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885GABRB1 2621/4885LMNA 3372/4885 |
| US-20210171500-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB1 1305/4885LMNA 1879/4885 |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | WEE2, WEE1, KAT2A | GABRA1 4685/4885GABRB1 4435/4885LMNA 2157/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB1 1305/4885LMNA 1879/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | GABRA1 1883/4885GABRB1 1763/4885LMNA 2671/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885GABRB1 2621/4885LMNA 3372/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | GABRA1 1969/4885GABRB1 1893/4885LMNA 2791/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | GABRA1 3223/4885GABRB1 3089/4885LMNA 3719/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | GABRA1 2064/4885GABRB1 2621/4885LMNA 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.